, Tracking Stock Market Picks
Enter Symbol:
Rating: GHDX
Underweight $25

Genomic Health, Inc. (NASDAQ: GHDX) rated to Underweight with price target $25 by Barclays

Wednesday,  Sep 2, 2015  1:25 PM ET by Dave Ficere

Barclays rated Genomic Health,
Inc. (NASDAQ: GHDX) to Underweight with price target $25.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy